Get the Stockscreener App
10.72
15.02%
1.40
After Hours:
11.54
0.82
+7.65%
Nextcure Inc stock is traded at $10.72, with a volume of 84,063.
It is up +15.02% in the last 24 hours and down -2.81% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
See More
Previous Close:
$9.32
Open:
$9.23
24h Volume:
84,063
Relative Volume:
1.67
Market Cap:
$38.67M
Revenue:
-
Net Income/Loss:
$-55.84M
P/E Ratio:
-0.6093
EPS:
-17.5951
Net Cash Flow:
$-49.61M
1W Performance:
+19.91%
1M Performance:
-2.81%
6M Performance:
+9.16%
1Y Performance:
+2,336%
1-Day Range:
$9.05
$10.87
1-Week Range:
$8.5201
$10.87
52-Week Range:
$0.3412
$15.74
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
10.72 | 33.62M | 0 | -55.84M | -49.61M | -17.60 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
NextCure initiates dose optimization study for ovarian cancer drug - Investing.com
Biotechnology company NextCure Inc. announced it is accelerating the progress of its R&D projects by expanding its clinical research center network to Canada and Europe. - bitget.com
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers - The Manila Times
NextCure initiates dose optimization study for ovarian cancer drug By Investing.com - Investing.com Canada
NextCure moves ovarian cancer drug into dose testing before ASCO - Stock Titan
What capacity utilization NextCure (NXTC)? (-2.47%) 2026-04-27Crowd Consensus Signals - Newser
NextCure (NXTC) Stock Rejected Order (Smart Money Exits) 2026-04-24Top Analyst Picks - Newser
NextCure (NASDAQ: NXTC) plans 2026 meeting, auditor, pay and equity plan votes - Stock Titan
NextCure to present SIM0505 cancer drug data at ASCO meeting - Investing.com
NextCure to present SIM0505 cancer drug data at ASCO meeting By Investing.com - Investing.com South Africa
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 - The Manila Times
NextCure and Simcere Announce Presentation of Phase 1 Data for SIM0505 at ASCO 2026 - Quiver Quantitative
NextCure Inc stock (US65343E1082): Is its immunotherapy pipeline strong enough to unlock biotech ups - AD HOC NEWS
Ladenburg Thalmann Upgrades NextCure (NXTC) - MSN
NXTC Forecast, Price Target & Analyst Ratings | NEXTCURE INC (NASDAQ:NXTC) - ChartMill
Resistance Check: Will Argan Inc benefit from rate cutsPortfolio Update Report & Risk Managed Trade Strategies - baoquankhu1.vn
GUOCHUN INTERNATIONAL INC. Reports No Revenue and Material Weaknesses in Q3 2025 10-Q/A Filing - Minichart
Published on: 2026-04-09 04:19:51 - baoquankhu1.vn
Surprises Report: Is NextCure Inc stock good for income investorsNew Guidance & Safe Entry Trade Signal Reports - baoquankhu1.vn
FDA Gives Fast Track Status to SIM0505 in Platinum-Resistant Ovarian Cancer - CancerNetwork
Activity Recap: Is NextCure Inc a defensive stock2026 News Drivers & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Is NextCure (NXTC) Stock heavily shorted | Price at $12.10, Up 8.67%High Volume Stocks - Newser
Value Recap: How is NextCure Inc managing supply chain issues2026 Geopolitical Influence & Verified Short-Term Plans - baoquankhu1.vn
NextCure Gets FDA Fast Track for SIM0505 in Ovarian Cancer - National Today
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer - Bitget
FDA fast-tracks NextCure ovarian cancer drug ahead of ASCO data - Stock Titan
Resistance Check: Is NextCure Inc exposed to currency risksMarket Performance Recap & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Trend Report: Will Investcorp Credit Management BDC Inc Preferred Security outperform tech stocksWeekly Investment Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
NXTC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
Sacral Fracture Risk After Short-Course RT for Rectal Cancer - Medscape
NXTC Stock Analysis: NextCure Inc. Biotech Gains 1.80 Percent to 10.72 Support Level - Cổng thông tin điện tử tỉnh Lào Cai
Buyout Rumor: Will American Tower Corporation stock go up in YEAR2026 Key Lessons & Stepwise Trade Signal Guides - baoquankhu1.vn
NXTC Should I Buy - Intellectia AI
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026 - The Manila Times
Phase 1 cancer drug abstract lands ASCO 2026 slot in Chicago - Stock Titan
Price Action: Is Oriental Culture Holding LTD stock a top performer YTD2026 Selloffs & Daily Entry Point Trade Alerts - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
BLRX PE Ratio & Valuation, Is BLRX Overvalued - Intellectia AI
Bond Watch: Is NextCure Inc stock showing strong momentumQuarterly Portfolio Summary & Verified Entry Point Signals - baoquankhu1.vn
NextCure, Inc.Common Stock (NQ: NXTC - FinancialContent
Retail Trends: Why is GGNPRB stock going downLong Setup & Smart Investment Allocation Insights - baoquankhu1.vn
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
NIVFPrice, Charts & Blockchain Insights - Intellectia AI
ITVI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MMMM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Buy Signal: Is NextCure Inc a defensive stockQuarterly Trade Review & Growth-Oriented Investment Plans - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Aug Action: Is CF Bankshares Incs growth already priced in2026 Chart Watch & Proven Capital Preservation Methods - baoquankhu1.vn
Published on: 2026-03-22 18:56:49 - baoquankhu1.vn
BOLD Technical Analysis & Price Forecast - Intellectia AI
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):